{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:12:37Z","timestamp":1792595557349,"version":"4.5.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1038\/nrd3115","type":"journal-article","created":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T09:35:37Z","timestamp":1277976937000},"page":"560-574","source":"Crossref","is-referenced-by-count":531,"title":["Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives"],"prefix":"10.1038","volume":"9","author":[{"given":"Harald","family":"Hampel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Broich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J.","family":"Teipel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell G.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Herholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun L. W.","family":"Bokde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne C.","family":"Hoessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy R.","family":"Sanhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd3115_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow, K., de Leon, M. J. & Zetterberg, H. Alzheimer's disease. Lancet 368, 387\u2013403 (2006).","journal-title":"Lancet"},{"key":"BFnrd3115_CR2","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1093\/brain\/awl280","volume":"129","author":"HW Klafki","year":"2006","unstructured":"Klafki, H. W., Staufenbiel, M., Kornhuber, J. & Wiltfang, J. Therapeutic approaches to Alzheimer's disease. Brain 129, 2840\u20132855, (2006).","journal-title":"Brain"},{"key":"BFnrd3115_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1326-4-19","volume":"4","author":"M Garcia-Alloza","year":"2009","unstructured":"Garcia-Alloza, M. et al. Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. Mol. Neurodegener. 4, 19 (2009).","journal-title":"Mol. Neurodegener."},{"key":"BFnrd3115_CR4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0197-4580(01)00245-7","volume":"22","author":"P Das","year":"2001","unstructured":"Das, P., Murphy, M. P., Younkin, L. H., Younkin, S. G. & Golde, T. E. Reduced effectiveness of A\u03b21\u201342 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging 22, 721\u2013727 (2001).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1172\/JCI25410","volume":"116","author":"Y Levites","year":"2006","unstructured":"Levites, Y. et al. Anti-A\u03b242- and anti-A\u03b240-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116, 193\u2013201 (2006).","journal-title":"J. Clin. Invest."},{"key":"BFnrd3115_CR6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer, R., Johnson, E., Ziegler-Graham, K., Arrighi, H. M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 3, 186\u2013191 (2007).","journal-title":"Alzheimers Dement."},{"key":"BFnrd3115_CR7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s12603-009-0036-7","volume":"13","author":"ER Siemers","year":"2009","unstructured":"Siemers, E. R. How can we recognize \u201cdisease modification\u201d effects? J. Nutr. Health Aging 13, 341\u2013343 (2009).","journal-title":"J. Nutr. Health Aging"},{"key":"BFnrd3115_CR8","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrd1130","volume":"2","author":"R Frank","year":"2003","unstructured":"Frank, R. & Hargreaves, R. Clinical biomarkers in drug discovery and development. Nature Rev. Drug Discov. 2, 566\u2013580, (2003).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3115_CR9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0197-4580(03)00002-2","volume":"24","author":"RA Frank","year":"2003","unstructured":"Frank, R. A. et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 24, 521\u2013536, (2003).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization. Neurology 61, 46\u201354 (2003).","journal-title":"Neurology"},{"key":"BFnrd3115_CR11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","volume":"2","author":"K Blennow","year":"2003","unstructured":"Blennow, K. & Hampel, H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2, 605\u2013613 (2003).","journal-title":"Lancet Neurol."},{"issue":"Suppl. 1","key":"BFnrd3115_CR12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00259-007-0703-z","volume":"35","author":"SJ Teipel","year":"2008","unstructured":"Teipel, S. J., Meindl, T., Grinberg, L., Heinsen, H. & Hampel, H. Novel MRI techniques in the assessment of dementia. Eur. J. Nucl. Med. Mol. Imaging 35 (Suppl. 1), 58\u201369 (2008).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrd3115_CR13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jalz.2007.08.006","volume":"4","author":"H Hampel","year":"2008","unstructured":"Hampel, H. et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 4, 38\u201348 (2008).","journal-title":"Alzheimers Dement."},{"key":"BFnrd3115_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-3-25","volume":"3","author":"P Whiting","year":"2003","unstructured":"Whiting, P., Rutjes, A. W., Reitsma, J. B., Bossuyt, P. M. & Kleijnen, J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med. Res. Methodol. 3, 25 (2003).","journal-title":"BMC Med. Res. Methodol."},{"key":"BFnrd3115_CR15","first-page":"76","volume":"7","author":"Z Nagy","year":"1996","unstructured":"Nagy, Z. et al. Hippocampal pathology reflects memory deficit and brain imaging measurements in Alzheimer's disease: clinicopathologic correlations using three sets of pathologic diagnostic criteria. Dementia 7, 76\u201381 (1996).","journal-title":"Dementia"},{"key":"BFnrd3115_CR16","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1098\/rstb.2002.1114","volume":"357","author":"NK Logothetis","year":"2002","unstructured":"Logothetis, N. K. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos. Trans. R. Soc. Lond. B Biol. Sci. 357, 1003\u20131037 (2002).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"BFnrd3115_CR17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.RES.44.1.127","volume":"44","author":"M Reivich","year":"1979","unstructured":"Reivich, M. et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ. Res. 44, 127\u2013137 (1979).","journal-title":"Circ. Res."},{"key":"BFnrd3115_CR18","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1093\/brain\/awm191","volume":"130","author":"A Lockhart","year":"2007","unstructured":"Lockhart, A. et al. PIB is a non-specific imaging marker of amyloid-\u03b2 (A\u03b2) peptide-related cerebral amyloidosis. Brain 130, 2607\u20132615 (2007).","journal-title":"Brain"},{"key":"BFnrd3115_CR19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/09540260802095099","volume":"20","author":"RF Allegri","year":"2008","unstructured":"Allegri, R. F., Glaser, F. B., Taragano, F. E. & Buschke, H. Mild cognitive impairment: believe it or not? Int. Rev. Psychiatry 20, 357\u2013363 (2008).","journal-title":"Int. Rev. Psychiatry"},{"key":"BFnrd3115_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/2009\/698156","volume":"21","author":"C Fennema-Notestine","year":"2009","unstructured":"Fennema-Notestine, C. et al. Structural neuroimaging in the detection and prognosis of pre-clinical and early AD. Behav. Neurol. 21, 3\u201312 (2009).","journal-title":"Behav. Neurol."},{"key":"BFnrd3115_CR21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0925-4927(95)02593-M","volume":"61","author":"JN Giedd","year":"1995","unstructured":"Giedd, J. N. et al. Reliability of cerebral measures in repeated examinations with magnetic resonance imaging. Psychiatry Res. 61, 113\u2013119 (1995).","journal-title":"Psychiatry Res."},{"key":"BFnrd3115_CR22","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.neurobiolaging.2005.05.032","volume":"27","author":"M Ewers","year":"2006","unstructured":"Ewers, M. et al. Multicenter assessment of reliability of cranial MRI. Neurobiol. Aging 27, 1051\u20131059 (2006).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JCP.0b013e31819a8f2e","volume":"29","author":"AL Bokde","year":"2009","unstructured":"Bokde, A. L. et al. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. J. Clin. Psychopharmacol. 29, 147\u2013156 (2009).","journal-title":"J. Clin. Psychopharmacol."},{"key":"BFnrd3115_CR24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2006.12.003","volume":"81","author":"JR Moffett","year":"2007","unstructured":"Moffett, J. R., Ross, B., Arun, P., Madhavarao, C. N. & Namboodiri, A. M. N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 81, 89\u2013131 (2007).","journal-title":"Prog. Neurobiol."},{"key":"BFnrd3115_CR25","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1259\/bjr\/60346217","volume":"80","author":"K Kantarci","year":"2007","unstructured":"Kantarci, K. 1H magnetic resonance spectroscopy in dementia. Br. J. Radiol. 80, S146\u2013S152 (2007).","journal-title":"Br. J. Radiol."},{"key":"BFnrd3115_CR26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/appi.ajp.159.5.738","volume":"159","author":"GE Alexander","year":"2002","unstructured":"Alexander, G. E., Chen, K., Pietrini, P., Rapoport, S. I. & Reiman, E. M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 159, 738\u2013745 (2002).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrd3115_CR27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1176\/jnp.16.4.488","volume":"16","author":"N Hirono","year":"2004","unstructured":"Hirono, N., Hashimoto, M., Ishii, K., Kazui, H. & Mori, E. One-year change in cerebral glucose metabolism in patients with Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 16, 488\u2013492 (2004).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"BFnrd3115_CR28","first-page":"88","volume":"5","author":"WD Heiss","year":"1994","unstructured":"Heiss, W. D., Kessler, J., Mielke, R., Szelies, B. & Herholz, K. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. Dementia 5, 88\u201398 (1994).","journal-title":"Dementia"},{"key":"BFnrd3115_CR29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archneur.62.5.721","volume":"62","author":"MS Mega","year":"2005","unstructured":"Mega, M. S. et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose F18 positron emission tomographic study. Arch. Neurol. 62, 721\u2013728 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnrd3115_CR30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00702-005-0312-6","volume":"113","author":"E Stefanova","year":"2006","unstructured":"Stefanova, E. et al. Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J. Neural Transm. 113, 205\u2013218 (2006).","journal-title":"J. Neural Transm."},{"key":"BFnrd3115_CR31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ana.21345","volume":"63","author":"A Kadir","year":"2008","unstructured":"Kadir, A. et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann. Neurol. 63, 621\u2013631 (2008).","journal-title":"Ann. Neurol."},{"key":"BFnrd3115_CR32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306\u2013319 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrd3115_CR33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/awm336","volume":"131","author":"CR Jack Jr","year":"2008","unstructured":"Jack, C. R. Jr et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131, 665\u2013680 (2008).","journal-title":"Brain"},{"key":"BFnrd3115_CR34","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1523\/JNEUROSCI.0673-07.2007","volume":"27","author":"J Maeda","year":"2007","unstructured":"Maeda, J. et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 27, 10957\u201310968 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrd3115_CR35","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","volume":"46","author":"VL Villemagne","year":"2008","unstructured":"Villemagne, V. L. et al. A\u03b2 deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688\u20131697 (2008).","journal-title":"Neuropsychologia"},{"key":"BFnrd3115_CR36","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.neurobiolaging.2007.03.029","volume":"29","author":"A Forsberg","year":"2008","unstructured":"Forsberg, A. et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 1456\u20131465, (2008).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe, C. C. et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7, 129\u2013135 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrd3115_CR38","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0306-4522(99)00476-5","volume":"95","author":"M Bobinski","year":"2000","unstructured":"Bobinski, M. et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 95, 721\u2013725 (2000).","journal-title":"Neuroscience"},{"key":"BFnrd3115_CR39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","volume":"6","author":"B Vellas","year":"2009","unstructured":"Vellas, B. et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144\u2013151 (2009).","journal-title":"Curr. Alzheimer Res."},{"key":"BFnrd3115_CR40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s12603-009-0047-4","volume":"13","author":"D Saumier","year":"2009","unstructured":"Saumier, D. et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. J. Nutr. Health Aging 13, 370\u2013372 (2009).","journal-title":"J. Nutr. Health Aging"},{"key":"BFnrd3115_CR41","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold, D. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genet. 41, 1088\u20131093 (2009).","journal-title":"Nature Genet."},{"key":"BFnrd3115_CR42","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genet. 41, 1094\u20131099 (2009).","journal-title":"Nature Genet."},{"key":"BFnrd3115_CR43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1052-5149(03)00092-3","volume":"13","author":"WE Klunk","year":"2003","unstructured":"Klunk, W. E. et al. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin. N. Am. 13, 781\u2013789 (2003).","journal-title":"Neuroimaging Clin. N. Am."},{"key":"BFnrd3115_CR44","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1176\/ajp.2007.164.6.916","volume":"164","author":"K Chen","year":"2007","unstructured":"Chen, K. et al. Correlations between apolipoprotein E \u025b4 gene dose and whole brain atrophy rates. Am. J. Psychiatry 164, 916\u2013921 (2007).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrd3115_CR45","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.1073\/pnas.052587399","volume":"99","author":"RI Scahill","year":"2002","unstructured":"Scahill, R. I., Schott, J. M., Stevens, J. M., Rossor, M. N. & Fox, N. C. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc. Natl Acad. Sci. USA 99, 4703\u20134707 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3115_CR46","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner, D. et al. Secreted amyloid \u03b2-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864\u2013870 (1996).","journal-title":"Nature Med."},{"key":"BFnrd3115_CR47","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2007.16","volume":"39","author":"AJ Myers","year":"2007","unstructured":"Myers, A. J. et al. A survey of genetic human cortical gene expression. Nature Genet. 39, 1494\u20131499 (2007).","journal-title":"Nature Genet."},{"key":"BFnrd3115_CR48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10048-008-0150-4","volume":"10","author":"JS Kauwe","year":"2009","unstructured":"Kauwe, J. S. et al. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid \u03b2. Neurogenetics 10, 13\u201317 (2009).","journal-title":"Neurogenetics"},{"key":"BFnrd3115_CR49","doi-asserted-by":"crossref","first-page":"8050","DOI":"10.1073\/pnas.0801227105","volume":"105","author":"JS Kauwe","year":"2008","unstructured":"Kauwe, J. S. et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-\u03b2 deposition. Proc. Natl Acad. Sci. USA 105, 8050\u20138054 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3115_CR50","doi-asserted-by":"crossref","first-page":"e1000072","DOI":"10.1371\/journal.pgen.1000072","volume":"4","author":"D Melzer","year":"2008","unstructured":"Melzer, D. et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 4, e1000072 (2008).","journal-title":"PLoS Genet."},{"key":"BFnrd3115_CR51","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2217\/14622416.9.7.847","volume":"9","author":"O Makeeva","year":"2008","unstructured":"Makeeva, O., Stepanov, V., Puzyrev, V., Goldstein, D. B. & Grossman, I. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics 9, 847\u2013868 (2008).","journal-title":"Pharmacogenomics"},{"key":"BFnrd3115_CR52","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.1995.03530200063039","volume":"274","author":"LA Farrer","year":"1995","unstructured":"Farrer, L. A. et al. Statement on use of apolipoprotein E testing for Alzheimer disease. American College of Medical Genetics\/American Society of Human Genetics Working Group on ApoE and Alzheimer disease. JAMA 274, 1627\u20131629 (1995).","journal-title":"JAMA"},{"key":"BFnrd3115_CR53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0809578","volume":"361","author":"RC Green","year":"2009","unstructured":"Green, R. C. et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N. Engl. J. Med. 361, 245\u2013254 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3115_CR54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.neurobiolaging.2006.02.001","volume":"28","author":"SK Herukka","year":"2007","unstructured":"Herukka, S. K. et al. CSF A\u03b242, Tau and phosphorylated Tau, APOE \u025b4 allele and MCI type in progressive MCI. Neurobiol. Aging 28, 507\u2013514 (2007).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR55","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray, S. et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Med. 13, 1359\u20131362 (2007).","journal-title":"Nature Med."},{"key":"BFnrd3115_CR56","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1602\/neurorx.1.2.226","volume":"1","author":"MC Irizarry","year":"2004","unstructured":"Irizarry, M. C. Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226\u2013234 (2004).","journal-title":"NeuroRx"},{"key":"BFnrd3115_CR57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/13506120009146438","volume":"7","author":"H Vanderstichele","year":"2000","unstructured":"Vanderstichele, H. et al. Standardization of measurement of beta-amyloid(1\u201342) in cerebrospinal fluid and plasma. Amyloid 7, 245\u2013258 (2000).","journal-title":"Amyloid"},{"key":"BFnrd3115_CR58","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.wad.0000194014.43575.fd","volume":"19","author":"ER Peskind","year":"2005","unstructured":"Peskind, E. R. et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis. Assoc. Disord. 19, 220\u2013225 (2005).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrd3115_CR59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","volume":"1","author":"K Blennow","year":"2004","unstructured":"Blennow, K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213\u2013225 (2004).","journal-title":"NeuroRx"},{"key":"BFnrd3115_CR60","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk, D., Blennow, K., White, L. R. & Launer, L. J. CSF A\u03b2 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652\u2013656 (2003).","journal-title":"Neurology"},{"key":"BFnrd3115_CR61","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann. Neurol. 59, 512\u2013519 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrd3115_CR62","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger, K. et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035\u20133041 (2006).","journal-title":"Brain"},{"key":"BFnrd3115_CR63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw, L. M. et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403\u2013413, (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrd3115_CR64","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1474-4422(09)70139-5","volume":"8","author":"PJ Visser","year":"2009","unstructured":"Visser, P. J. et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8, 619\u2013627, (2009).","journal-title":"Lancet Neurol."},{"key":"BFnrd3115_CR65","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385\u2013393, (2009).","journal-title":"JAMA"},{"key":"BFnrd3115_CR66","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/17520363.1.1.59","volume":"1","author":"U Andreasson","year":"2007","unstructured":"Andreasson, U., Portelius, E., Andersson, M. E., Blennow, K. & Zetterberg, H. Aspects of \u03b2-amyloid as a biomarker for Alzheimer's disease. Biomarkers Med. 1, 59\u201378 (2007).","journal-title":"Biomarkers Med."},{"key":"BFnrd3115_CR67","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1515\/CCLM.2007.320","volume":"45","author":"D de Jong","year":"2007","unstructured":"de Jong, D., Kremer, B. P., Olde Rikkert, M. G. & Verbeek, M. M. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin. Chem. Lab. Med. 45, 1421\u20131434 (2007).","journal-title":"Clin. Chem. Lab. Med."},{"key":"BFnrd3115_CR68","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/archpsyc.64.6.718","volume":"64","author":"Z Zhong","year":"2007","unstructured":"Zhong, Z. et al. Levels of \u03b2-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 64, 718\u2013726 (2007).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrd3115_CR69","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1001\/archneur.65.8.1102","volume":"65","author":"H Zetterberg","year":"2008","unstructured":"Zetterberg, H. et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 65, 1102\u20131107 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrd3115_CR70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3940(01)01586-5","volume":"300","author":"P Davidsson","year":"2001","unstructured":"Davidsson, P. et al. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci. Lett. 300, 157\u2013160 (2001).","journal-title":"Neurosci. Lett."},{"key":"BFnrd3115_CR71","doi-asserted-by":"crossref","first-page":"14538","DOI":"10.1074\/jbc.273.23.14538","volume":"273","author":"H von der Kammer","year":"1998","unstructured":"von der Kammer, H. et al. Muscarinic acetylcholine receptors activate expression of the EGR gene family of transcription factors. J. Biol. Chem. 273, 14538\u201314544 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnrd3115_CR72","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2007.03.064","volume":"419","author":"K Blennow","year":"2007","unstructured":"Blennow, K. et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci. Lett. 419, 18\u201322 (2007).","journal-title":"Neurosci. Lett."},{"key":"BFnrd3115_CR73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3233\/JAD-2007-12307","volume":"12","author":"H Zetterberg","year":"2007","unstructured":"Zetterberg, H. et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J. Alzheimers Dis. 12, 255\u2013260 (2007).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrd3115_CR74","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/jpet.103.060715","volume":"309","author":"TA Lanz","year":"2004","unstructured":"Lanz, T. A., Hosley, J. D., Adams, W. J. & Merchant, K. M. Studies of A\u03b2 pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the \u03b3-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-L-alaninamide (LY-411575). J. Pharmacol. Exp. Ther. 309, 49\u201355 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd3115_CR75","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bcp.2004.11.015","volume":"69","author":"JJ Anderson","year":"2005","unstructured":"Anderson, J. J. et al. Reductions in \u03b2-amyloid concentrations in vivo by the \u03b3-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. 69, 689\u2013698 (2005).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrd3115_CR76","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","volume":"65","author":"AS Fleisher","year":"2008","unstructured":"Fleisher, A. S. et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch. Neurol. 65, 1031\u20131038 (2008).","journal-title":"Arch. Neurol."},{"key":"BFnrd3115_CR77","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1124\/jpet.108.143628","volume":"328","author":"S Sankaranarayanan","year":"2009","unstructured":"Sankaranarayanan, S. et al. First demonstration of cerebrospinal fluid and plasma A\u03b2 lowering with oral administration of a \u03b2-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J. Pharmacol. Exp. Ther. 328, 131\u2013140 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd3115_CR78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.neuron.2008.06.018","volume":"59","author":"PA Adlard","year":"2008","unstructured":"Adlard, P. A. et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A\u03b2. Neuron 59, 43\u201355 (2008).","journal-title":"Neuron"},{"key":"BFnrd3115_CR79","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","volume":"7","author":"L Lannfelt","year":"2008","unstructured":"Lannfelt, L. et al. Safety, efficacy, and biomarker findings of PBT2 in targeting A\u03b2 as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 7, 779\u2013786 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrd3115_CR80","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","volume":"297","author":"C Hesse","year":"2001","unstructured":"Hesse, C. et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297, 187\u2013190 (2001).","journal-title":"Neurosci. Lett."},{"key":"BFnrd3115_CR81","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archneur.63.9.1277","volume":"63","author":"H Zetterberg","year":"2006","unstructured":"Zetterberg, H. et al. Neurochemical aftermath of amateur boxing. Arch. Neurol. 63, 1277\u20131280 (2006).","journal-title":"Arch. Neurol."},{"key":"BFnrd3115_CR82","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","volume":"64","author":"S Gilman","year":"2005","unstructured":"Gilman, S. et al. Clinical effects of A\u03b2 immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64, 1553\u20131562 (2005).","journal-title":"Neurology"},{"key":"BFnrd3115_CR83","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000107099","volume":"24","author":"M Degerman Gunnarsson","year":"2007","unstructured":"Degerman Gunnarsson, M., Kilander, L., Basun, H. & Lannfelt, L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 24, 247\u2013252 (2007).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrd3115_CR84","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J. et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707\u2013712 (1989).","journal-title":"Science"},{"key":"BFnrd3115_CR85","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734\u2013746 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrd3115_CR86","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jalz.2009.01.019","volume":"5","author":"MC Carrillo","year":"2009","unstructured":"Carrillo, M. C. et al. Early risk assessment for Alzheimer's disease. Alzheimers Dement. 5, 182\u2013196 (2009).","journal-title":"Alzheimers Dement."},{"key":"BFnrd3115_CR87","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0891988705281881","volume":"18","author":"M Coats","year":"2005","unstructured":"Coats, M. & Morris, J. C. Antecedent biomarkers of Alzheimer's disease: the adult children study. J. Geriatr. Psychiatry Neurol. 18, 242\u2013244 (2005).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"BFnrd3115_CR88","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446\u2013452 (2006).","journal-title":"Neurology"},{"key":"BFnrd3115_CR89","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/sim.1718","volume":"23","author":"RB Mani","year":"2004","unstructured":"Mani, R. B. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat. Med. 23, 305\u2013314 (2004).","journal-title":"Stat. Med."},{"key":"BFnrd3115_CR90","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","volume":"93","author":"MS Pepe","year":"2001","unstructured":"Pepe, M. S. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054\u20131061 (2001).","journal-title":"J. Natl Cancer Inst."},{"issue":"Suppl. 5","key":"BFnrd3115_CR91","first-page":"10","volume":"11","author":"P Leber","year":"1997","unstructured":"Leber, P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis. Assoc. Disord. 11 (Suppl. 5), 10\u201321; discussion 37\u201319 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrd3115_CR92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.59.090506.155819","volume":"59","author":"J Woodcock","year":"2008","unstructured":"Woodcock, J. & Woosley, R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1\u201312 (2008).","journal-title":"Annu. Rev. Med."},{"key":"BFnrd3115_CR93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","volume":"1","author":"R Katz","year":"2004","unstructured":"Katz, R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1, 189\u2013195 (2004).","journal-title":"NeuroRx"},{"key":"BFnrd3115_CR94","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","volume":"282","author":"R Temple","year":"1999","unstructured":"Temple, R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 282, 790\u2013795 (1999).","journal-title":"JAMA"},{"key":"BFnrd3115_CR95","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2288-3-16","volume":"3","author":"SG Baker","year":"2003","unstructured":"Baker, S. G. & Kramer, B. S. A perfect correlate does not a surrogate make. BMC Med. Res. Methodol. 3, 16 (2003).","journal-title":"BMC Med. Res. Methodol."},{"key":"BFnrd3115_CR96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","volume":"125","author":"TR Fleming","year":"1996","unstructured":"Fleming, T. R. & DeMets, D. L. Surrogate end points in clinical trials: are we being misled? Ann. Intern. Med. 125, 605\u2013613 (1996).","journal-title":"Ann. Intern. Med."},{"key":"BFnrd3115_CR97","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","volume":"64","author":"NC Fox","year":"2005","unstructured":"Fox, N. C. et al. Effects of A\u03b2eta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64, 1563\u20131572 (2005).","journal-title":"Neurology"},{"key":"BFnrd3115_CR98","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/jmri.21049","volume":"27","author":"CR Jack Jr","year":"2008","unstructured":"Jack, C. R. Jr et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 27, 685\u2013691 (2008).","journal-title":"J. Magn. Reson. Imaging"},{"key":"BFnrd3115_CR99","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jalz.2005.06.003","volume":"1","author":"SG Mueller","year":"2005","unstructured":"Mueller, S. G. et al. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 1, 55\u201366 (2005).","journal-title":"Alzheimers Dement."},{"key":"BFnrd3115_CR100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrd2174","volume":"5","author":"SA Williams","year":"2006","unstructured":"Williams, S. A., Slavin, D. E., Wagner, J. A. & Webster, C. J. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nature Rev. Drug Discov. 5, 897\u2013902 (2006).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd3115_CR101","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrc1911","volume":"6","author":"S Gutman","year":"2006","unstructured":"Gutman, S. & Kessler, L. G. The US Food and Drug Administration perspective on cancer biomarker development. Nature Rev. Cancer 6, 565\u2013571 (2006).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrd3115_CR102","doi-asserted-by":"crossref","first-page":"T166","DOI":"10.1016\/j.jalz.2008.05.436","volume":"4","author":"M Grundman","year":"2008","unstructured":"Grundman, M. & Black, R. O3-04-05: clinical trials of bapineuzumab, a \u03b2-amyloid-targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimers Dement. 4, T166 (2008).","journal-title":"Alzheimers Dement."},{"key":"BFnrd3115_CR103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddtec.2007.10.003","volume":"4","author":"WR Sanhai","year":"2007","unstructured":"Sanhai, W. R., Spiegel, J. & Ferrari, M. A critical path approach to advance nanoengineered medical products. Drug Discov. Today Technol. 4, 35\u201341 (2007).","journal-title":"Drug Discov. Today Technol."},{"key":"BFnrd3115_CR104","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/archneur.64.6.849","volume":"64","author":"BH Ridha","year":"2007","unstructured":"Ridha, B. H. et al. Application of automated medial temporal lobe atrophy scale to Alzheimer disease. Arch. Neurol. 64, 849\u2013854 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrd3115_CR105","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0925-4927(96)02790-4","volume":"67","author":"CE Byrum","year":"1996","unstructured":"Byrum, C. E. et al. Accuracy and reproducibility of brain and tissue volumes using a magnetic resonance segmentation method. Psychiatry Res. 67, 215\u2013234 (1996).","journal-title":"Psychiatry Res."},{"key":"BFnrd3115_CR106","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1212\/WNL.49.3.786","volume":"49","author":"CR Jack Jr","year":"1997","unstructured":"Jack, C. R. Jr et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49, 786\u2013794 (1997).","journal-title":"Neurology"},{"key":"BFnrd3115_CR107","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.neurobiolaging.2005.10.002","volume":"27","author":"PN Wang","year":"2006","unstructured":"Wang, P. N., Lirng, J. F., Lin, K. N., Chang, F. C. & Liu, H. C. Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan. Neurobiol. Aging 27, 1797\u20131806, (2006).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR108","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archneur.57.3.339","volume":"57","author":"NC Fox","year":"2000","unstructured":"Fox, N. C., Cousens, S., Scahill, R., Harvey, R. J. & Rossor, M. N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch. Neurol. 57, 339\u2013344 (2000).","journal-title":"Arch. Neurol."},{"key":"BFnrd3115_CR109","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00004647-200105000-00014","volume":"21","author":"I Loubinoux","year":"2001","unstructured":"Loubinoux, I. et al. Within-session and between-session reproducibility of cerebral sensorimotor activation: a test\u2013retest effect evidenced with functional magnetic resonance imaging. J. Cereb. Blood Flow Metab. 21, 592\u2013607 (2001).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"BFnrd3115_CR110","first-page":"1006","volume":"13","author":"TT Kircher","year":"2005","unstructured":"Kircher, T. T., Erb, M., Grodd, W. & Leube, D. T. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. Am. J. Geriatr. Psychiatry 13, 1006\u20131013 (2005).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrd3115_CR111","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JCP.0b013e31819a8f2e","volume":"29","author":"ALW Bokde","year":"2009","unstructured":"Bokde, A. L. W. et al. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease. J. Clin. Psychopharmacol. 29, 147\u2013156 (2009).","journal-title":"J. Clin. Psychopharmacol."},{"key":"BFnrd3115_CR112","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/brain\/awh671","volume":"129","author":"R Goekoop","year":"2006","unstructured":"Goekoop, R., Scheltens, P., Barkhof, F. & Rombouts, S. A. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation \u2014 a pharmacological fMRI study. Brain 129, 141\u2013157 (2006).","journal-title":"Brain"},{"key":"BFnrd3115_CR113","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1212\/01.WNL.0000149638.45635.FF","volume":"64","author":"LL Chao","year":"2005","unstructured":"Chao, L. L. et al. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 64, 282\u2013289 (2005).","journal-title":"Neurology"},{"key":"BFnrd3115_CR114","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1212\/01.wnl.0000228218.68451.31","volume":"67","author":"F Jessen","year":"2006","unstructured":"Jessen, F. et al. Treatment monitoring and response prediction with proton MR spectroscopy in AD. Neurology 67, 528\u2013530 (2006).","journal-title":"Neurology"},{"key":"BFnrd3115_CR115","first-page":"1460","volume":"34","author":"K Herholz","year":"1993","unstructured":"Herholz, K. et al. Comparability of FDG PET studies in probable Alzheimer's disease. J. Nucl. Med. 34, 1460\u20131466 (1993).","journal-title":"J. Nucl. Med."},{"key":"BFnrd3115_CR116","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison, P. et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68, 501\u2013508 (2007).","journal-title":"Neurology"},{"key":"BFnrd3115_CR117","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/jcbfm.1988.104","volume":"8","author":"WD Heiss","year":"1988","unstructured":"Heiss, W. D. et al. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J. Cereb. Blood Flow Metab. 8, 613\u2013617 (1988).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"BFnrd3115_CR118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00213-006-0408-1","volume":"187","author":"SJ Teipel","year":"2006","unstructured":"Teipel, S. J. et al. Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl.) 187, 86\u201394 (2006).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnrd3115_CR119","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/brain\/awl178","volume":"129","author":"H Engler","year":"2006","unstructured":"Engler, H. et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856\u20132866 (2006).","journal-title":"Brain"},{"key":"BFnrd3115_CR120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jnnp.2004.038729","volume":"76","author":"NI Bohnen","year":"2005","unstructured":"Bohnen, N. I. et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 76, 315\u2013319 (2005).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrd3115_CR121","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen, N. et al. Cerebrospinal fluid \u03b2-amyloid(1\u201342) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 56, 673\u2013680 (1999).","journal-title":"Arch. Neurol."},{"key":"BFnrd3115_CR122","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1373\/clinchem.2004.039347","volume":"51","author":"A Olsson","year":"2005","unstructured":"Olsson, A. et al. Simultaneous measurement of \u03b2-amyloid(1\u201342), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336\u2013345 (2005).","journal-title":"Clin. Chem."},{"key":"BFnrd3115_CR123","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000008156","volume":"43","author":"R Fukuyama","year":"2000","unstructured":"Fukuyama, R. et al. Age-dependent change in the levels of A\u03b240 and A\u03b242 in cerebrospinal fluid from control subjects, and a decrease in the ratio of A\u03b242 to A\u03b240 level in cerebrospinal fluid from Alzheimer's disease patients. Eur. Neurol. 43, 155\u2013160 (2000).","journal-title":"Eur. Neurol."},{"key":"BFnrd3115_CR124","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410440108","volume":"44","author":"M Kanai","year":"1998","unstructured":"Kanai, M. et al. Longitudinal study of cerebrospinal fluid levels of tau, A\u03b21\u201340, and A\u03b2eta1\u201342(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 44, 17\u201326 (1998).","journal-title":"Ann. Neurol."},{"key":"BFnrd3115_CR125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0197-4580(03)00086-1","volume":"25","author":"P Lewczuk","year":"2004","unstructured":"Lewczuk, P. et al. Neurochemical diagnosis of Alzheimer's dementia by CSF A\u03b242, A\u03b242\/A\u03b240 ratio and total tau. Neurobiol. Aging 25, 273\u2013281 (2004).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR126","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000100926","volume":"23","author":"O Hansson","year":"2007","unstructured":"Hansson, O. et al. Prediction of Alzheimer's disease using the CSF A\u03b242\/A\u03b240 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23, 316\u2013320 (2007).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrd3115_CR127","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-510X(98)00122-1","volume":"158","author":"M Shoji","year":"1998","unstructured":"Shoji, M. et al. Combination assay of CSF tau, A\u03b21\u201340 and A\u03b21\u201342(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 158, 134\u2013140 (1998).","journal-title":"J. Neurol. Sci."},{"key":"BFnrd3115_CR128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(02)01038-8","volume":"333","author":"MJ de Leon","year":"2002","unstructured":"de Leon, M. J. et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci. Lett. 333, 183\u2013186 (2002).","journal-title":"Neurosci. Lett."},{"key":"BFnrd3115_CR129","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.neurobiolaging.2005.07.003","volume":"27","author":"MJ de Leon","year":"2006","unstructured":"de Leon, M. J. et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging 27, 394\u2013401 (2006).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd3115_CR130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0014-4886(03)00027-X","volume":"183","author":"A Olsson","year":"2003","unstructured":"Olsson, A. et al. Measurement of \u03b1- and \u03b2-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp. Neurol. 183, 74\u201380 (2003).","journal-title":"Exp. Neurol."},{"key":"BFnrd3115_CR131","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1373\/clinchem.2006.066720","volume":"52","author":"JH Verheijen","year":"2006","unstructured":"Verheijen, J. H. et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin. Chem. 52, 1168\u20131174 (2006).","journal-title":"Clin. Chem."},{"key":"BFnrd3115_CR132","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/01.wnl.0000229925.52203.4c","volume":"67","author":"RM Holsinger","year":"2006","unstructured":"Holsinger, R. M., Lee, J. S., Boyd, A., Masters, C. L. & Collins, S. J. CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias. Neurology 67, 710\u2013712 (2006).","journal-title":"Neurology"},{"key":"BFnrd3115_CR133","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ana.20144","volume":"55","author":"RM Holsinger","year":"2004","unstructured":"Holsinger, R. M., McLean, C. A., Collins, S. J., Masters, C. L. & Evin, G. Increased beta-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann. Neurol. 55, 898\u2013899 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrd3115_CR134","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1073\/pnas.0409336102","volume":"102","author":"DG Georganopoulou","year":"2005","unstructured":"Georganopoulou, D. G. et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl Acad. Sci. USA 102, 2273\u20132276 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd3115_CR135","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","volume":"44","author":"H Vanderstichele","year":"2006","unstructured":"Vanderstichele, H. et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin. Chem. Lab. Med. 44, 1472\u20131480 (2006).","journal-title":"Clin. Chem. Lab. Med."},{"key":"BFnrd3115_CR136","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen, E. et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 285, 49\u201352, (2000).","journal-title":"Neurosci. Lett."},{"key":"BFnrd3115_CR137","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01178-2","volume":"287","author":"R Kohnken","year":"2000","unstructured":"Kohnken, R. et al. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 287, 187\u2013190 (2000).","journal-title":"Neurosci. Lett."},{"key":"BFnrd3115_CR138","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel, H. et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61, 95\u2013102 (2004).","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd3115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3115","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:03:29Z","timestamp":1684469009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd3115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":138,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["BFnrd3115"],"URL":"https:\/\/doi.org\/10.1038\/nrd3115","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}